The Analgesic Efficacy of Perineural Nalbuphine as an Adjuvant to Bupivacaine in Ultrasound Guided Superficial Cervical Plexus Nerve Block for Thyroid Surgeries. A Double Blinded Randomized Controlled Trial.
Recruiting now · Phase 2
Conditions studied: Intra and Postoperative Pain Management
In brief
This study aiming to evaluate the analgesic effect of adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries regarding first rescue analgesia in the first twenty-four hours postoperative, VAS score after extubation and complications such as postoperative nausea, vomiting and respiratory depression.
Key facts
- Study ID
- NCT06633068
- Run by
- Cairo University
- People needed
- 54
- Starts
- 2024-07-15
- Expected to finish
- 2025-07-01
- Last updated by the study team
- 2024-10-09
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Patients aged between 18 to 60 years old of both sexes undergoing elective thyroid surgery.
- ASA I and II.
You may not qualify if…
- Patient refusal.
- Hypersensitivity or contraindication to nalbuphine or bupivacaine.
- Pregnancy or lactating mothers.
- Hepatic, cardiac or renal diseases.
- Bleeding disorders.
- Severe neurological or psychological disorders.
- Goitres with retrosternal extension.
- Any anatomical disruption in the neck (ex: metastatic lymph nodes).
Where it is running
- Kasr Alainy Teaching Hospitals — Giza, الجيزة, Egypt (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.